BEAMSTART Logo

Korea approves Daewoong Pharmaceutical's diabetes drug

Korea Economic Daily LogoKorea Economic Daily2 mo ago

Korea approves Daewoong Pharmaceutical's diabetes drug - Korea Economic Daily

Quick Summary:

DAEWOONG PHARMACEUTICAL has received domestic approval for its diabetes drug Envlo with the active ingredient enavogliflozin, the second straight year for the company to release a self-developed medication following last year's Fexuclue, which treats gastroesophageal reflux with the active ingredient Fexuprazan.

CEO Lee Chang-jae said, "The independent development of Korea's first drug using an SGLT2 inhibitor, the most notable diabetes treatment on the global market, is a significant achievement," adding, "We will seek to raise the quality of life of diabetic patients at home and abroad by providing the best new diabetes drugs to them".

Daewoong Pharmaceutical said the global market for diabetes treatment using SGLT2 inhibitors last year was worth about 27 trillion won ($20.7 billion), with the Korean market alone valued at 150 billion won.


More Pictures

Korea approves Daewoong Pharmaceutical's diabetes drug - Korea Economic Daily (Picture 1)

or

Article Details

Category: Economy

Markets:

Topics:

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2022-12-02 @ 11:08:02 (2 months ago)

News Timezone: GMT +8:00

Ranking: #334 (out of 6603 stories this day)

News Source URL: kedglobal.com

Language: English

Article Length: 336 words

Reading Time: 2 minutes read

Sentences: 16 lines

Sentence Length: 21 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Korea Economic Daily

News ID: 2156125

View Article Analysis

About Korea Economic Daily

Korea Economic Daily Logo

Main Topics: Economy

Official Website: kedglobal.com

Update Frequency: 7 posts per day

Year Established: 1964

Headquarters: South Korea

News Last Updated: 1 hours ago

Coverage Areas: South Korea

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #91

Publisher Details

Frequently Asked Questions

How long will it take to read this news story?

The story "Korea approves Daewoong Pharmaceutical's diabetes drug" has 336 words across 16 sentences, which will take approximately 2 - 3 minutes for the average person to read.

Which news outlet covered this story?

The story "Korea approves Daewoong Pharmaceutical's diabetes drug" was covered 2 months ago by Korea Economic Daily, a news publisher based in South Korea.

How trustworthy is 'Korea Economic Daily' news outlet?

Korea Economic Daily is a fully independent (privately-owned) news outlet established in 1964 that covers mostly economy news.

The outlet is headquartered in South Korea and publishes an average of 7 news stories per day.

It's most recent story was published 1 hours ago.

What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
  • News ID: #2156125
  • URL: https://beamstart.com/news/korea-approves-daewoong-pharmaceuticals-diabetes-1

BEAMSTART brings you the latest news, database, and jobs from all around the world on startups, technology, and business. Stay updated with industry news, plug-in to exciting community events, and discover incredible career opportunities with the world's most innovative companies.

© Copyright 2023 BEAMSTART. All Rights Reserved.